
## Ilaria Fiordoliva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2449930/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. European Journal of Cancer, 2021, 144, 41-48.	2.8	64
2	BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma. Journal of Thoracic Disease, 2021, 13, 5741-5751.	1.4	5
3	Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis. Lung Cancer, 2020, 146, 318-326.	2.0	9
4	Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 151, 102974.	4.4	17
5	Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer Journal of Clinical Oncology, 2020, 38, 3074-3074.	1.6	5
6	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. Scientific Reports, 2019, 9, 12993.	3.3	21
7	Developments in the management of advanced soft-tissue sarcoma – olaratumab in context. OncoTargets and Therapy, 2018, Volume 11, 833-842.	2.0	13
8	Managing hyponatremia in lung cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 711-719.	3.2	29
9	Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma. Tumori, 2016, 102, 190-195.	1.1	9
10	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 2016, 11, e0152079.	2.5	38
11	Hyponatremia in cancer patients: Time for a new approach. Critical Reviews in Oncology/Hematology, 2016, 102, 15-25.	4.4	50
12	Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.8	1